openbell openbell

Financial news scored by AI. No noise, no delay. Latest: FDA Approves Regeneron's Livsayis for Generalized Myasthenia Gravis (Impact: +75). OpenBell scores breaking market news for potential price impact, so you can see why it matters, not just that it happened.

Financial News with AI Impact Scores

Get real-time financial news with AI-powered impact analysis delivered through Discord

Today's Market Overview

openbell provides real-time news intelligence for smarter trades. Latest stories cover Healthcare, Consumer Cyclical sectors. Top story: "FDA Approves Regeneron's Livsayis for Generalized Myasthenia Gravis" with +75 impact score. Join our Discord community for real-time alerts and discussions.

Latest News

Healthcare +75 REGN

FDA Approves Regeneron's Livsayis for Generalized Myasthenia Gravis

The FDA approved Regeneron Pharmaceuticals’ Livsayis (cemdisiran) for adults with generalized myasthenia gravis who test positive for anti-acetylcholine receptor antibodies. The C5-directed siRNA therapy is injected subcutaneously four times a year, a dosing frequency the company says is unique among gMG treatments, and approval was supported by Phase 3 NIMBLE trial results showing rapid, sustained disease control. Livsayis is Regeneron’s first approved siRNA therapy and its first neurology medicine; the article reports no financial figures or stock-price impact.

Consumer Cyclical +65 INEO

INNEOVA Holdings Limited Reports Q3 2026 Financial Results and Strategic Expansion

INNEOVA Holdings reported record nine-month revenue of $53.59 million, up 17.6% year over year. In Q3, gross margin rose to 12.6%, up 465 basis points sequentially, and adjusted EBITDA improved about 18%; since year-end, total debt fell 34% and liabilities declined 18.2%, including settlement of an $8.0 million convertible note. The company entered Saudi Arabia through a five-year distribution agreement targeting an initial 126,000-unit order, expanded its Pharma Cell partnership in Albania, and signed a DIABIT-IS X commercialization agreement in Greece. By September 30, it had repurchased 255,600 shares under its $5.0 million buyback program.